| Document |
Document Title |
|
WO/2024/028519A1 |
The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, X, Y and A are as defined herein. These compounds are photodynamic agents that generates reactive oxygen species when subjected to UV radiation. The invention also...
|
|
WO/2024/031041A2 |
Disclosed is an oxygen-containing heterocyclic compound, and use thereof. The present disclosure provides an oxygen-containing heterocyclic compound represented by Formula I, a pharmaceutically acceptable salt thereof, deuterated derivat...
|
|
WO/2024/022528A1 |
Disclosed are compounds having general formula I, a method for preparing same, a pharmaceutical composition thereof, and use thereof. Specifically, the present invention provides a compound having a structure represented by general formu...
|
|
WO/2024/025896A2 |
Provided are protein kinase C (PKC) theta inhibitor compounds. Also provided are methods of use of such compounds, as well as pharmaceutical compositions thereof.
|
|
WO/2024/022372A1 |
The present disclosure relates to an antibody-drug conjugate and the use thereof. Specifically, provided is an antibody-drug conjugate as represented by formula I, or a stereoisomer thereof, a prodrug thereof, a pharmaceutically acceptab...
|
|
WO/2024/026323A1 |
Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the ...
|
|
WO/2024/022165A1 |
The present invention provides a series of structurally novel exatecan derivatives, pharmaceutically acceptable salts, stereoisomers or prodrugs thereof, and use thereof in the field of anti-tumor. The exatecan derivatives have a structu...
|
|
WO/2024/026129A2 |
The invention provides novel tricyclic aryl compounds and derivatives thereof, and pharmaceutical compositions thereof and methods for treating diseases and disorders, such as various types of cancer.
|
|
WO/2024/022244A1 |
The present application relates to a heterocyclic compound having biological activity represented by formula (I), a preparation method therefor and a pharmaceutical composition thereof, and further relates to an use of such a compound an...
|
|
WO/2024/022167A1 |
The present invention provides a novel camptothecin derivative compound, a pharmaceutically acceptable salt, a stereoisomer, or a prodrug thereof, and a method for preparing same and use thereof. The compound has a structure represented ...
|
|
WO/2024/022520A1 |
A toxin molecule suitable for an antibody-drug conjugate is provided. Specifically, a compound represented by the following formula (I), or a pharmaceutically acceptable salt or hydrate thereof is provided. The compound can be used to pr...
|
|
WO/2024/026061A1 |
The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which lowering mutant huntingtin protein ("mHTT") in a subject i...
|
|
WO/2024/020734A1 |
Provided are methods for preparing camptothecin derivatives and their synthetic precursors.
|
|
WO/2024/020380A1 |
Substituted quinazoline compounds, conjugates, and pharmaceutical compositions for use in the treatment of cancer are disclosed herein. The disclosed compounds are useful, among other things, in the inhibition of CDK. In certain aspects,...
|
|
WO/2024/017380A1 |
Disclosed in the present invention are a tricyclic-containing macrocyclic compound and a use thereof, and particularly disclosed are a compound as shown in formula (II) and a pharmaceutically acceptable salt thereof.
|
|
WO/2024/020419A1 |
Substituted aza-quinazoline compounds, conjugates, and pharmaceutical compositions for use in the treatment of cancer are disclosed herein. The disclosed compounds are useful, among other things, in the inhibition of CDK. In certain aspe...
|
|
WO/2024/020536A1 |
Disclosed are topoisomerase inhibitor compounds as cytotoxic agents and further as payloads for antibody-drug conjugates. Also disclosed are methods of making and use of the compounds in the treatment of proliferative diseases.
|
|
WO/2024/015346A1 |
Described herein are compounds and conjugates of Formulae I and II and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as cereblon-binding agents and bifunctional degraders for ce...
|
|
WO/2024/014837A1 |
The present invention relates to: (a) an active camptothecin derivative represented by chemical formula 1, which is designed to bind to a DDX5 protein and E3 ligase; (b) a prodrug thereof designed to release the active camptothecin deriv...
|
|
WO/2024/015229A1 |
Provided herein are compounds, conjugate products thereof, methods, and pharmaceutical compositions for use in treatment and diagnosis.
|
|
WO/2024/012557A1 |
Provided herein are anti-apoptotic BCL-2 family protein degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or m...
|
|
WO/2024/012523A1 |
A bioactive conjugate, and a preparation method therefor and the use thereof. Specifically, disclosed are an antibody-drug conjugate as represented by formula (XV), a preparation method therefor and the use thereof in the prevention and/...
|
|
WO/2024/015497A1 |
This disclosure relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof, in which all of the variables in Formula (I) are as defined in the application. The compounds of this disclosure are capable of inhibiting ...
|
|
WO/2024/012308A1 |
A PRMT5 inhibitor, a preparation method therefor, and the pharmaceutical use thereof. In particular, the present invention relates to a PRMT5 inhibitor having a structure of formula (I), a preparation method therefor, a pharmaceutical co...
|
|
WO/2023/280638A9 |
The application relates to vinyl thianthrenium compounds Vinyl- TT+X- of the Formula (I), a process for preparing the same and the use thereof for vinylating organic compounds.
|
|
WO/2024/012791A1 |
The present invention relates to an electrochemical process for the synthesis of pyrazolines and pyrazoles of formula (I). The process can be especially used for the synthesis of the herbicide safener mefenpyr-diethyl.
|
|
WO/2024/012524A1 |
The present disclosure relates to a bioactive conjugate, and a preparation method therefor and the use thereof. Specifically, disclosed are an antibody-drug conjugate as represented by formula XV, and a preparation method therefor and th...
|
|
WO/2024/015408A1 |
Described herein are compounds of Formula I and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as estrogen receptor degraders).
|
|
WO/2024/015793A2 |
The present invention concerns a novel enantiomer of 9-(3-fluorophenyl)-5-(2- hydroxyethyl)-6,9-dihydro-[l,3]dioxolo[4,5-g]furo[3,4-b]quin
olin-8(5H)-one (SU056), as well as pharmaceutically acceptable salts thereof, pharmaceutical compo...
|
|
WO/2024/007851A1 |
A catalyst for amide synthesis and preparation and use thereof are disclosed. The catalyst is a thio or seleno pyranodipyrimidine compound and has a simple and novel structure, high catalytic efficiency, and good atom economy. The cataly...
|
|
WO/2024/008044A1 |
A compound, which is a compound represented by formula (I) or a stereoisomer, tautomer, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof. The compound represented by formula (I) can significantly i...
|
|
WO/2024/008113A1 |
The present invention relates to a formamide-substituted heterotricyclic derivative represented by formula (I), a method for preparing same, and use thereof. The present invention further relates to a pharmaceutical composition comprisin...
|
|
WO/2024/010782A1 |
Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R1, R3, X, Y, Z, and W arc as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a pr...
|
|
WO/2024/008680A1 |
The present invention generally relates to compounds inhibiting dipeptidyl peptidase 1 activity; particularly the invention relates to compounds that are azetidine derivatives, including pharmaceutically acceptable salts thereof, methods...
|
|
WO/2024/011155A1 |
Described herein are oxazole TRPML1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of TRPML1-mediated disorders or diseases.
|
|
WO/2024/002205A1 |
Provided is a bifunctional compound, or a pharmaceutically acceptable salt, hydrate, solvate, metabolite or prodrug thereof, wherein the bifunctional compound is represented by Formula (I) : ABM-L-CLM (I); wherein: ABM is an androgen rec...
|
|
WO/2024/006559A1 |
Compounds are provided for inhibiting NLRP3 inflammasome generally, or for treating a NLRP3 inflammasome dependent condition more specifically, by contacting the NLRP3 inflammasome or administering to a subject in need thereof, respectiv...
|
|
WO/2024/006916A1 |
Provided herein are compounds useful as inhibitors of Janus kinase (JAK) proteins and in treating JAK-related diseases.
|
|
WO/2024/005431A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2024/005526A1 |
The present invention relates to a novel compound as an NADPH oxidase 2 inhibitor and a pharmaceutical composition containing same. More specifically, the compound according to the present invention exhibits selective and excellent inhib...
|
|
WO/2024/002263A1 |
Disclosed are a series of amino-substituted heteroaryl and use thereof, and in particular, disclosed are a compound represented by formula (IV) and a pharmaceutically acceptable salt thereof.
|
|
WO/2024/002377A1 |
Provided is a class of compounds with methyltransferase inhibitory activity. Specifically, provided is a class of compounds with PRMT5 inhibitory activity. The compounds can be used for preparing a pharmaceutical composition for treating...
|
|
WO/2024/006776A1 |
The application relates to bifunctional compounds which act as degraders of the estrogen receptor alpha (ERα) and are useful for treating disorders associated with ERα-mediated transcription regulation such as endometriosis and cancer....
|
|
WO/2024/005506A1 |
The present invention relates to a novel compound with inhibitory activity against NADPH oxidase 2 (NOX2) and a use thereof. The compound of the present invention, an isomer thereof, or a pharmaceutically acceptable salt thereof has the ...
|
|
WO/2024/006881A1 |
Provided herein are compounds and compositions thereof that reduce WEE1 kinase protein levels. In some embodiments, the compounds and compositions are provided for treatment WEE1 associated diseases such as cancer.
|
|
WO/2024/006977A1 |
This invention reports rational design, synthesis, and characterization of a series of a delta opioid receptor (DOR)-selective bitopic ligands targeting a conserved sodium site in DOR. The design is based on modifications in a selective ...
|
|
WO/2024/002376A1 |
The present invention provides a class of compounds with inhibitory activity against methyltransferases. Particularly, the present invention provides a class of compounds with inhibitory activity against PRMT5. The compounds can be used ...
|
|
WO/2024/005486A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting element comprising same.
|
|
WO/2023/247670A1 |
The present invention provides compounds of formula (I) CB (I) or pharmaceutically acceptable salts thereof, wherein R3 to R5, R4a, B and C are as described herein, compositions including the compounds, processes of manufacturing the com...
|
|
WO/2023/249473A1 |
The present invention relates to an antibody-drug conjugate (ADC) having a drug-linker conjugate (A) linked thereto and a preparation method therefor, wherein the drug-linker conjugate includes a combination of a camptothecin-based drug ...
|
